ATP13A2 regulates mitochondrial bioenergetics through macroautophagy

Area of Science:

• Neuroscience
• Cell Biology
• Genetics

Background:

• Mitochondrial dysfunction and impaired autophagy are hallmarks of Parkinson's disease (PD).
• Mutations in ATP13A2 cause a rare form of autosomal recessive parkinsonism, but its precise role remains unclear.
• Lysosomes and autophagy are crucial for clearing damaged mitochondria, maintaining cellular health.

Purpose of the Study:

• To investigate the impact of ATP13A2 loss-of-function on mitochondrial integrity and cellular function.
• To determine if ATP13A2 deficiency affects autophagic processes, particularly mitophagy.
• To explore the link between ATP13A2, mitochondrial health, and oxidative stress in the context of PD.

Main Methods:

• ATP13A2 was knocked down in primary mouse cortical neurons and SH-SY5Y cells using siRNA.
• Mitochondrial mass, oxygen consumption, ATP levels, mitochondrial morphology, and reactive oxygen species (ROS) production were assessed.
• Autophagy markers (LC3-II), autophagic flux, and mTOR signaling were analyzed.
• The role of autophagy was further investigated by inhibiting autophagy induction using siRNA against Atg7.

Main Results:

• ATP13A2 knockdown resulted in increased mitochondrial mass, oxygen consumption, and ROS production.
• Mitochondria in ATP13A2-deficient cells showed increased fragmentation.
• Autophagic flux was decreased, with elevated phospho-mTOR and resistance to rapamycin-induced autophagy.
• Inhibition of autophagy induction mimicked the effects of ATP13A2 knockdown on mitochondrial parameters and ROS production.

Conclusions:

• Loss of ATP13A2 function impairs mitochondrial quality control by disrupting autophagy.
• This disruption leads to increased mitochondrial mass, oxidative stress, and fragmentation, contributing to PD pathogenesis.
• These findings highlight the critical role of ATP13A2 in maintaining mitochondrial homeostasis and suggest therapeutic targets for PD.